PD-1/CTLA-4 抗体联合免疫治疗晚期胃癌患者所致不良反应的护理-现代护理医学杂志-CSCIED科技核心评价数据库-手机版

PD-1/CTLA-4 抗体联合免疫治疗晚期胃癌患者所致不良反应的护理

Nursing care of adverse reactions caused by pd-1/ctla-4 combined immunotherapy in patients with advancedgastric cancer

ES评分 0 浏览量：504 下载量：0

DOI	10.12208/j. jmnm.202200130
刊名	现代护理医学杂志 Journal of Modern Nursing MedicineJPCNS
年，卷(期)	2022, 1(2)
作者	付玉*,卢静,刘晓红,
作者单位	北京大学肿瘤医院北京 ;
摘要	目的：针对当前 PD-1/CTLA-4 抗体联合免疫治疗用于晚期胃癌患者的效果开展深入分析，探讨晚期胃癌患者用药后出现的不良反应及护理措施。方法：选择了 2019 年 9 月 1 日到 2020 年 10 月 1 日在我科使用 PD-1/CTLA-4 抗体联合免疫治疗的晚期胃癌患者为研究对象，回顾性分析患者在治疗过程中出现的不良反应，并给予相应的护理措施。结果：在 52 例患者中，经有效的药物治疗和护理干预后，药物不良反应减轻或消除。结论：PD-1/CTLA-4 联合免疫治疗患者存在一定的不良反应，其直接危害患者身体健康，应全面评估患者的健康状况和既往病史，密切观察患者出现的不良反应，并积极采取相应的治疗及护理措施，增强患者的耐受性和依从性，以保证患者能顺利完成用药，达到控制疾病的目的。
Abstract	Objective: to analyze the effect of PD-1/CTLA-4 combined immunotherapy on patients with advanced gastric cancer, and to explore the adverse effects and nursing measures in patients with advanced gastric cancer. Methods: Patients with advanced gastric cancer diagnosed, treated and nursed in our hospital from september1, 2019 to october1,2020 were selected as the research objects. The adverse effect of patients during treatment were retrospectively analyzed and corresponding nursing measures were given. Results: after effective drug treatment and nursing intervention, the adverse effect was reduced or eliminated in 52 patients. Conclusion: Patients with PD-1/CTLA-4 combined immunotherapy have certain adverse effect, which directly endanger the health of patients. It is necessary to comprehensively evaluate the health status and past medical history of patients, closely observe the adverse effect of patients, and actively take corresponding nursing measures and drug treatment to enhance the tolerance and compliance of patients, so as to ensure that patients can successfully complete the medication.
关键词	PD-1/CTLA-4 抗体联合免疫治疗；不良反应；常规护理；晚期胃癌
KeyWord	PD-1/CTLA-4 combined immunotherapy; Adverse effect; Routine nursing; Advanced gastriccancer
基金项目
页码	194-196

参考文献
相关文献

[1] 白慧霞.中国胃癌发病率及死亡率研究进展[J].临床医药文献杂志,2019,6(07):192.

[2] 刘甜,胡毅.PD-1/PD-L1 抑制剂免疫相关性不良反应及其处理综述[ J ].解放军医学院学报,2018,39(3):251-254.

[3] 吴晓滨,罗辉兴,翁诺卿 AP3M2 在胃癌中的作用及临床意义分析 . 消化肿瘤杂志（电子版）, 2020 ,12(4) :238-241,247

[4] 韩俊婷,王蕊,康桂娟等.当归补血汤改善急性重型颅脑创伤营养状态的疗效观察[J].武警后勤学院学报(医学版),2019,28(01):24-27,34.

[5] 李晨茜,杨蓓.护理干预在预防肺癌患者心血管系统并的应用效果[J].中国肿瘤临床与康复,2017,24(07):863-866.

[6] 王光杰,李莲港,姜军. 免疫检查点抑制剂心脏不良反应研究现状[J]. 中华肿瘤防治杂志, 2018, 25(20):71-77.

[7] 曾秀娟, 黄旭霞, 邝绮华, et al. Pembrolizumab 联合化疗治疗恶性肿瘤的护理 [J]. 全科护理 , 2019,17(02):100-101.

[8] 蔡育志,廖海华,韩靖,等 BORIS 蛋白表达在胃癌中的表达及其预后价值 . 岭南现代临床外科 , 2019 ,19(3) :260-263

[9] Bray Freddie,Ferlay Jacques,Torre Lindsey A.,etc.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].2018,68(6).

[10] Seigo,Minami,Shouichi,etc.Pretreatment Lung Immune Prognostic Index Is a Prognostic Marker of Chemotherapy and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor[J].2019,10(1).

引用本文

付玉*,卢静,刘晓红. PD-1/CTLA-4 抗体联合免疫治疗晚期胃癌患者所致不良反应的护理 [J]. 现代护理医学杂志. 2022; 1; (2). 194 - 196.

文献评论

相关学者

相关机构